Clinical Trials Browser

Phase 2 × Thalidomide × Thoracic × Clear all

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT04382300 2021-01-28

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03062800 2019-06-05

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00281827 2017-12-28

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Phase 2 Terminated

22 enrolled 11 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03341494 2017-11-14

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00053300 2010-06-10

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

Lung Neoplasms

NCT00114192 2010-02-01

Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms